Lorazepam NDC 60760-947

NDC codes

FDA NDC Directory

Product NDC (as listed)60760-947Labeler and product segments. Claims need a package NDC.

Product NDC at billing width60760-0947Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
60760-947-02	60760094702	2 TABLET in 1 BOTTLE, PLASTIC (60760-947-02)Marketed from Jul 7, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lorazepam
Generic name (nonproprietary): lorazepam
Active ingredients: Lorazepam — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: St. Mary's Medical Park Pharmacy
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 218597
Marketing start: Jul 7, 2026
Listing expires: Dec 31, 2027
DEA schedule: CIV
Other FDA classes: Benzodiazepines (Chemical structure)
Identifiers: Product ID 60760-947_560930d7-50b0-041d-e063-6294a90ab00dSPL ID 560930d7-50b0-041d-e063-6294a90ab00dSPL set ID 56093df3-10f6-e747-e063-6294a90a6564RxCUI 197900UNII O26FZP769L
Pharmacologic class: Benzodiazepine

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N460760094702 followed by a unit qualifier and the quantity

Package 60760-0947-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 7, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Lorazepam tablets are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam tablets in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 218597

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 218597
Product	Strength	Form · route	Labeler	Product NDC
Lorazepam	Lorazepam .5 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-627
Lorazepam	Lorazepam 1 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-628
Lorazepam	Lorazepam 2 mg/1	TabletOral	Rising Pharma Holdings, Inc.	64980-629
Lorazepam	Lorazepam 1 mg/1	TabletOral	St. Mary's Medical Park Pharmacy	60760-948